Drugs Information

Optimax

noreply@blogger.com (obatinfo) — Mon, 26 Oct 2009 16:29:00 +0000

OPTIMAX
KAPLET SALUT SELAPUT

Komposisi :

Tiap kaplet salut selaput mengandung	Takaran per saji	% AKG*
Lutein	3 mg	-
Lycopene	2 mg	-
Vitamin E	25 mg	500,00 %
Vitamin C	100 mg	333,33 %
Seng	10 mg	133,33 %
β-karoten	6000 IU	-
Ekstrak Bilberry	80 mg	-

* % AKG (Angka Kecukupan gizi) berdasarkan pada diet 2000 kalori

OPTIMAX mengandung bahan-bahan antioksidan dan mineral.
Lutein adalah satu-satunya karotenoid yang terkonsentrasi pada daerah retina mata.
Kombinasi lycopene dan β-karoten, vitamin C, Seng dan vitamin E dapat membantu memelihara kesehatan tubuh, terutama kesehatan fungsi mata.

Kegunaan :
Suplemen untuk memelihara kesehatan fungsi mata dan memperbaiki mikrosirkulasi retina mata.

Petunjuk penggunaan :
1 kaplet salut selaput 2 kali sehari.

Efek Samping:
Tidak ada efek samping apabila digunakan dalam batas takaran yang dianjurkan.

Peringatan dan Perhatian :

Kandungan vitamin E dalam OPTIMAX dapat memperpanjang waktu pembekuan darah, sebaiknya hindari penggunaan bersamaan dengan antikoagulan.
OPTIMAX tidak efektif bila dikonsumsi bersamaan dengan antasida dan makanan.

Interaksi Obat:
Penggunaan bersamaan dengan minuman beralkohol dapat meningkatkan kejadian hepatotoksisitas (studi preliminary (pendahuluan) pada hewan mengenai β-karoten), Antasida dan antikoagulan.

Kemasan dan Nomor Registrasi:
Kotak, 5 strip @ 6 kaplet salut selaput: POM. SD. 021 504 481

SIMPAN DI TEMPAT KERING, PADA SUHU DI BAWAH 30° C, TERLINDUNG DARI CAHAYA.
JAUHKAN DARI JANGKAUAN ANAK-ANAK.

Diproduksi oleh
PT. DEXA MEDICA
Palembang - Indonesia

Untuk
PT. FERRON PAR PHARMACEUTICALS
Jakarta - Indonesia

Itzol

noreply@blogger.com (obatinfo) — Mon, 14 Sep 2009 07:58:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Interpec

noreply@blogger.com (obatinfo) — Mon, 14 Sep 2009 06:24:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Lapibal

noreply@blogger.com (obatinfo) — Mon, 14 Sep 2009 06:14:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Inclarin

noreply@blogger.com (obatinfo) — Sun, 13 Sep 2009 16:49:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Inadryl Sirop

noreply@blogger.com (obatinfo) — Sun, 13 Sep 2009 12:29:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Interhistin

noreply@blogger.com (obatinfo) — Sun, 13 Sep 2009 11:56:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Theobron

noreply@blogger.com (obatinfo) — Fri, 11 Sep 2009 08:40:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Tomit Injeksi

noreply@blogger.com (obatinfo) — Fri, 11 Sep 2009 08:11:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Infeld Gel

noreply@blogger.com (obatinfo) — Fri, 11 Sep 2009 07:39:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Inerson

noreply@blogger.com (obatinfo) — Thu, 10 Sep 2009 06:22:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Colme

noreply@blogger.com (obatinfo) — Wed, 09 Sep 2009 08:55:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Digenta

noreply@blogger.com (obatinfo) — Wed, 09 Sep 2009 04:19:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Moisderm

noreply@blogger.com (obatinfo) — Wed, 09 Sep 2009 03:44:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Inbion Kapsul

noreply@blogger.com (obatinfo) — Wed, 09 Sep 2009 03:28:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Antox Kapsul

noreply@blogger.com (obatinfo) — Wed, 09 Sep 2009 02:57:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Remufit

noreply@blogger.com (obatinfo) — Sat, 05 Sep 2009 23:50:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Stimuno

noreply@blogger.com (obatinfo) — Sat, 05 Sep 2009 16:30:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Stimuno Forte

noreply@blogger.com (obatinfo) — Sat, 05 Sep 2009 16:26:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Claneksi Kaplet, Syrup

noreply@blogger.com (obatinfo) — Wed, 02 Sep 2009 17:54:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Aspar-K Tablet

noreply@blogger.com (obatinfo) — Wed, 02 Sep 2009 07:52:00 +0000

ASPAR®-K
POTASSIUM ASPARTATE PREPARATION
Reg. No. DKL7625202517A1

COMPOSITION & DESCRIPTION

Generic name : Potassium L-aspartate
White crystalline powder: odorless
Freely soluble in water and practically insoluble in ethanol or acetone.

Product's name	Content of Potassium L-aspartate	Description of the product
ASPAR®-K tablet	300 mg per tablet (K : 1,8 mEq)	White film-coated tablet

ACTIONS
PHARMACOLOGICAL ACTIONS:
A potassium ion, one of the main electrolytes in the cell, has actions such as to induce the membrane potential, to maintain the osmotic presssure and to control the acid-base equilibrium. When the red blood cell is employed as a sample to examine the transport of potassium into the tissues, Potassium L-aspartate proves a better intake by the tissue than potassium chloride.

ABSORPTION AND EXCRETION:
When the amount of Potassium L-aspartate equivalent to 20 mEq/kg/day of potassium was administered for 32 days to rats fed on food lacking potassium for 24 days, the mean amount of potassium excreted in the feces was 26,1 µEq/head/day. Namely, the absorption rate of potassium from the intestines was not less than 99,5 % because the mean administration amount of potassium was 5497 µEq/head/day.

TOXICOLOGY AND TERATOLOGY:

Acute toxicity:
The LD₅₀ of Potassium L-aspartate in male rats is not less than 10,000 mg/kg, 4,061 mg/kg, 1,500 mg/kg and 667 mg/kg by oral, subcutaneous, intraperitoneal and intravenous routes respectively.
Chronic toxicity:
After administration of 4 g/kg/day of ASPAR@-K in oral route and 1 g/kg/day in intraperitoneal route to male and female rats for 3 months, no significant difference was observed in general condition urinary findings hemafological findings and pathohistological findings between administration group and control group.
Teratology:
Fetal toxicity in mice and rats was evaluated in accordance with the Measurements for Safety of Drugs by the Japanese Ministry of Health & Welfare, and no significant difference was observed between administration and control group.

INDICATIONS
Potassium supplement in the following diseases and symptoms accompanied with abnormal balance of electrolytes:

Cardiac diseases
Liver diseases
Periodic tetraplegia due to hypokalemia
Hypokalemia due to prolonged administration of anti-hypertensive diuretics, adrenal cortical steroids digitalis and insulin.
Other disorders of potassium metabolism (pre- and post-operative course, diarrhea, vomiting).

ADMINISTRATION AND DOSAGE
Take 1 to 3 tablets three times per day.
The dose may be increased according to the severity of symptoms and condition of patients.

CAUTIONS ON USE

CONTRAINDICATION:

Patient with Addison's disease untreated
Patient with hyperkalemia
Patients with hypersensitivity to the drug component

USES WITH CAUTION:
On administration to those patients with advanced hypofunctioned or damage kidneys including those suspected of such disorders, whose serum and urinary electrolytes should be carefully examined.
ADVERSE REACTION:

Digestive system : Anorexia and gastric disturbances have been encountered.
Heart : Precordial heavy feeling has been noted

IT IS ADVISABLE NOT TO ADMINISTER THE DRUG to premature infants, newborns and infants because the drug is reported to cause at 250 mg/kg or more as aspartic acid some histopathological change in the nucleus arciformis of the hypothalamus in mice and rats at the age of 3 weeks or below.
INTERACTION:
Since the following drugs may cause hyperkalemia, concurrent use with them should be exercised with much care.

Antialdosterone preparation
Triamterene

CAUTION ON HANDLING
Store in a tight and light-resistant container at below 30°C.

PRESENTATION
Box of 10 aluminum strips of 10 tablets

Manufactured by
PT. TANABE INDONESIA
Bandung, Indonesia

Under license from
TANABE SEIYAKU CO., LTD.
Osaka, Japan

Dumocalcin Tablet

noreply@blogger.com (obatinfo) — Wed, 02 Sep 2009 07:36:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Callusol

noreply@blogger.com (obatinfo) — Mon, 31 Aug 2009 08:32:00 +0000

We apologize for this inconvenience, this post is only available in Indonesian version.
We will provide it soon.

Click here to view the post

Duphaston Tablet

noreply@blogger.com (obatinfo) — Mon, 31 Aug 2009 08:18:00 +0000

Duphaston
dydrogesterone
20 tablets

Solvay
Pharmaceuticals

COMPOSITION
Each tablet contains; dydrogesterone 10 mg

MODE OF ACTION
Dydrogesterone is an orally-active pcogestogen which produces a complete secretory endometrium in an oestrogen-primed uterus thereby providing protection for estrogen induced increased risk for endometrium hyperplasia and / or carcinogenesis. It is indicated of endogenous progesterone deficiency.
Dydrogesterone has no estrogenic, no androgenic, no thermogenic, no anabolic, and no corticoid activity.

INDICATIONS

Infertility due to luteal insufficiency.
Threatened abortion which is related to luteal deficiency.
Habitual abortion associated with proven progesterone deficiency.
Amenorrhoea (secondary)
Function uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer.
Endometriosis
Dysmenorrnoea (primary) unrelated to an obvious physical cause such as uterine polyps, pelvic inflammatory disease or uterine leiomyomata. Adjunct to oestrogen replacement therapy.

POSOLOGY
Dosage in infertility due to tuteal insufficiency
10 mg dydrogesterone twice daily from the 11th to the 25th day of the cycle. The treatment is to be continued for at least 6 successive cycles, it is advised to continue this treatment during the first few months of a possible pregnancy, at dosages as are recommended for habitual abortion.

Dosage in threatened abortion which is related to luteal deficiency
Intial dose: 40 mg Duphaston at once, followed by 10 mg every 8 hours until symptom cease. Increase the dose by 10 mg every 8 hours when the symptoms recur or do not disappear during treatment. After the symptoms have disappeared, the effective dose should be maintained for 1 week and reduced gradually if the symptom is not recur.

Dosage in habitual abortion associated with proven progesterone deficiency
Treatment should be started as soon as possible, preferably, before conception. 10 mg dydrogesterone twice daily is to be given from the 11th to the 25th day of the cycle with continuous administration after conception. The treatment must be continued at any rate until the 20th week of pregnancy, then the dose can be reduced gradually.

Dosage in amenorrhoea (secondary)

An oestrogen once daily from day 1 to 25 of the cycle, and Duphaston 10 mg twice daily from day 11 to 25.
In oligomenorrhoea (functional amenorrhoea): 10 mg daily for five days will induce withdrawal bleeding in most patients.

Dosage in abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology [functional bleeding), such as submucous fibroids or uterine cancer

To arrest functional bleeding: 10 to 20 mg (1 to 2 tablets) one or two times a day for five to ten days.
To prevent further heavy bleeding: 10 to 20 mg (1 to 2 tablets) one or two times a day from the 11th to 25th day of the menstrual cycle and repeated cyclically as needed.

Dosage in endometriosis
10 mg twice daily starting with the 5" day of the menstrual cycle and ending on the 25th day. An alternative regimen is continuous administration.

Dosage In dysmenormoea (primary)
Unrelated to an obvious physical cause such as uterine polyps, pelvic inflammatory disease or uterine leiomyomi.
10 mg twice daily starting with the 5th day of the menstrual cycle and ending on the 25th day.

Adjunct to oestrogen replacement therapy
10 mg daily for 10 to 12 days per month is adequate for most patients.
20 mg daily for 10 to 12 days per month should be used only in the event unacceptable withdrawal bleeding.

OVERDOSAGE
Overdosage may cause nausea and withdrawal bleeding may occur in females. In case of overdoses or accidental ingestion, children should be observed closely although no medication is required. Gastric lavage or syrup of ipecacuanha may be given if deemed necessary. Therapy with Duphaston tablets must be adapted to the specific indications and therapeutic response of the individual patient, all dosage schedules assume the interval between menses to be 28 days.

PRECAUTIONS AND WARNING
Breakthrough bleeding may occur in a few patients. This can, however, be prevented by increasing the dosage. As a general rule, HRT should not be prescribed without a yearly generally physical examination, including a gynaecology examination. A mammogram on regular intervals Is generally advised. Breakthrough bleedings or abnormal findings at the gynaecological examination may be an indication for endometrial assessment.

Although not reported with the use of dydrogesterone, progestogens have been associated with the occurrence of several serious conditions including thromboembolism, stroke, myocardial infarction, hepatic adenoma, gall bladder disease, and hypertension, which have occurred in patients using oral contraceptives containing oestrogens and progestogens. The doctor should therefore be aware of these disorders and the drug should be discontinued immediately they occur or are suspected.

It is known that progestogens may cause some degree of fluid retention. Though this has never been reported for dydrogesterone, patients with epilepsy, migraine, asthma and cardiac or renal dysfunctions should be carefully observed while on therapy as fluid retention may be a factor.
Patients with history of psychic depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
Any possible influence of prolonged dydrogesterone therapy on pituitary, ovarian, adrenal, hepatic or uterine function awaits further study.
Masculinisation has been observed In patients receiving certain progestogens.
Dydrogesterone is a progestogen, but to date female masculinisation has not been observed with this agent.
The use of progestational agents during the first four months of pregnancy is not recommended.
Detectable amounts of progestogens have been identified in the milk of mothers receiving them. The effect of this on the breastfed infant has not been determined.
Therefore Duphaston are not recommended for women who are breast feeding.

SIDE EFFECTS

Breakthrough bleeding may occur. This can, however, be prevented by increasing the dosage.
Nausea, breast tenderness, headache, bloated feeling, transient dizziness and skin reaction have occasionally been reported.
Menstrual changes, oedema, weight change are common.
Other adverse reactions that have been occasionally reported include hair abnormalities, vision changes, depression, confusion, abdominal pain, hepatitis, shortness of breath and slurred speech.
Although not reported with the use of dydrogesterone, an increased risk of the following serious adverse reactions has been associated with the use of oral contraceptives containing oestrogens and progestogens: thrombophlebitis, pulmonary embolism, coronary thrombosis, cerebral thrombosis, cerebral haemorrhage, hypertension, gall bladder disease, liver tumors, congenital anomalies.
There is evidence of and association between the following conditions and the use of oral contraceptives, although additional confirmatory studies are needed: mesenteric thrombosis, neuro-ocular lesions e.g. retinal thrombosis and optic neuritis.

CONTRAINDICATIONS
Undiagnosed abnormal vaginal bleeding.
Thrombophlebitis or thromboembolic disorders. Cerebrovascular or coronary artery disease, or a past history of these conditions. Missed abortion. Known or suspected carcinoma of the breast. Known or suspected carcinoma of genital organs. Hepatic disease or dysfunction, a history of cholestatic jaundice or pruritus of pregnancy and in Dubin - Johnson syndrome and Rotor syndrome. History of herpes of pregnancy.
Sicklecell anaemia. Benign or malignant liver tumours which developed during the use of oral contraceptives.

STORAGE
Store below 30°C.

PACKING
Boxes of 20 tablets (1 blister of 20 tablets) Reg. No. DKI0681600617A1

ON MEDICAL PRESCRIPTION ONLY
HARUS DENGAN RESEP DOKTER

Manufactured by:
Solvay Pharmaceuticals B.V., Weesp, The Netherlands

Imported by:
PT. Solvay Pharma Indonesia, Jakarta, Indonesia

Bricasma Tablet

noreply@blogger.com (obatinfo) — Mon, 31 Aug 2009 08:09:00 +0000

Bricasma® tablet
terbutaline sulphate
Selective bronchodilator

Composition
Each tablet contain Terbutaline Sulphate 2.5 mg

Characteristics
Bricasma is a sympathomimetic bronchodilator with a degree of selective B2 stimulant activity on the respiratory system.
Bricasma increases impaired mucocillary clearance in obstructive lung diseases and improves the transport of sticky mucous. The outstanding characteristics in all presentation is its long duration of action. Contary to the long known sympathomimetic amines that affect also the B1 receptors in the heart with consequent palpitation and discomforts for the patient. Therapeutic doses of Bricasma very seldom produce these effects.

Indication
For the release of bronchospasm in bronchial asthma, chronic bronchitis, emphysema and other diseases of the lung, where bronchoconstriction is a complicating factor.

Contraindications
Patients with a history of hypersensitivity to any of its component or sympathomimetic amines.
Patients with thyrotoxicosis should use Bricasma with caution.

Side effects
The frequency of side effects with oral bricasma is low.
Those recorded, e.g. tremor, and palpitations, are characteristic of symphatomimetic amines. In patients will disappear after a few days of treatment and if palpitation occur, these will subside if the dose is lowered.
Other commonly reported reactions include increased heart rate and dizziness.
Other reported reactions include headache, drowsiness vomiting, nausea, sweating, and muscle cramps. These reactions are generally transient and usually do not require treatment. There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis.

Dosage for adults
1 - 2 tablets, 2-3 times a day. In most patients the optimum single dose is 2 tablets. In patients being unusually sensitive to symphathomimetic amines, it is advisable to initiate treatment with 1 tablet 2-3 times a day.

A total dose of 15 mg in a 24 hour period should not be exceeded

Dosage for children
7-15 years : 25 mg, 2 - 3 times daily.

Precaution
Bricasma should not be given together with non-selective beta-blocker.
Terbutaline is not indicated and should not be used for the management of preterm labor. Serious adverse reactions have been reported following administration of Terbutaline sulfate to women in labor.
These reports have included transient hypokalemia, pulmonary edema ( sometimes after delivery ), and hypoglycemia in the mother and / or neonatal child. Maternal death has been reported with terbutaline sulfate and other drugs of this class.
There have been rare reports of seizures occuring in patients receiving terbutaline, which do not recur when the drug is discontinued and have not been explained on any other basis.
Terbutaline sulphate is a sympathomimetic amine and such should be used with caution in patients with cardiovascular disorders ( including arrythmias, coronary insufficiency and hypertension), in patients with hyperthyroidism or diabetes mellitus, history of seizures, or in patients who are unusually responsive to sympathomimetic amines.
Patients susceptible to hypokalemia should be monitored because transient early alls in serum potassium levels have been reported with β agonists. Immediate hypersensitivity reactions and exacerbation of bronchospasm have been reported after terbutaline administration.
There are, however, no adequate and well - controlled studies in pregnant women, this drug should be used during pregnancy only if clearly needed.
Terbutaline is excreted in breast milk. Caution should be exercised when this drug is administered to a nursing woman.
Safety and effectiveness in children below the age of 12 have not been established.

OVERDOSAGE
Too frequent administration, as with other sympathomimetic agents, may cause nausea, headaches, changes in blood pressure, anxiety, tension, insomnia, tremor. The symptoms and sign are those characteristic of excessive symphatetic stimulation.

Storage
Store below 30°C, protect from tight and moisture

Presentation
Box of 10 x 10 tablets in strips

HARUS DENGAN RESEP DOKTER
Reg. No.: DKL0008902610A1

Manufactured by:
PT AstraZeneca Indonesia
Jl. Raya Kasri 153, Pandaan, Jawa Timur

Trade Marks herein are the property of the AstraZeneca group